




NEET SS



GYNECOLOGY ONCOLOGY



CONTENT

1)	PRINCIPLE OF CHEMOTHERAPY	1
2)	PRINCIPLE OF RAFIOTHERAPY 1	10
3)	PRINCIPLE OF RAFIOTHERAPY 2	20
4)	HEREDITARY GYNECOLOGICAL CANCERS	31
5)	PRE INVASIVE LESION OF CERVIX 1	50
6)	PRE INVASIVE LESION OF CERVIX 2	59
7)	PRE INVASIVE LESION OF CERVIX 3	77
8)	PRE INVASIVE LESION OF CERVIX 4	91
9)	UTEINE SARCOMA	109
10)	ENDOMETRICAL CANCER 1	127
11)	ENDOMETRICAL CANCER 2	137
12)	FOGO 2023 UPDATE	148
13)	CERVICAL CANCER 1	153
14)	CERVICAL CANCER 2	164
15)	EPITHELIAL OVARIAN CANCER 1	174
16)	EPITHELIAL OVARIAN CANCER 2	180
17)	EPITHELIAL OVARIAN CANCER 3	190
18)	ADNEXAL MASS 1	197
19)	ADNEXAL MASS 2	205
20)	GCT & SEX CORD STROMAL TUMORS	212
21)	GTN 1	225
22)	GTN 2	236
23)	VULVAR INTRAEPITHELIAL NEOPLASIA	242
24)	VAGINAL MALIGNANCIES	252
25)	BREAST CANCER 1	260
26)	BREAST CANCER 2	268
27)	CA VULVA 1	275
28)	CA VULVA 2	
29)	CANCER PREGNANCY	282
30)	PALLIATIVE CARE IN GYNE ONCO	293
31)	SURGERY IN GYNAEC CANCER	301
32)	MIS IN GYNAEC CANCER	317

PRINCIPLES OF CHEMOTHERAPY

Cell cycle

00:01:33

Phases of cell cycle :

i. G₀ phase :

- Resting phase.
- Non-chemosensitive.
- Terminal differentiated cells stay in this phase or re-enter after quiescence.

ii. G₁ phase : Protein synthesis, RNA Synthesis and DNA repair.


iii. S phase : New DNA synthesis.

iv. G₂ phase :

- Premitotic.
- There is twice the DNA content.
- Prepare for division.

v. M phase : mitosis + chromosomal division.

Note : Growth fraction (GF) : The fraction of cells that are in the dividing phase.



Cell cycle and chemotherapeutic agents.

Classified as :

- Cell cycle non specific.
- Cell cycle specific.
- Combined (Synergism) : Enhances cell kill.

Cell cycle specific :

Acting on G₁ phase

Hormonal agents :

- Tamoxifen.
- Mestrol acetate.

Antitumor antibiotics :

- Doxorubicin liposome.
- Actinomycin.

Acting on S phase

Antimetabolites :

- Methotrexate.
- Gemcitabine.
- 5-Fluorouracil.

Acting on G₂ phase :

Topoisomerase inhibitors :

- Etoposide (Topoisomerase 2 inhibitor).
- Topotecan (Topoisomerase 1 inhibitor).
- Antitumor antibiotics :
Bleomycin.

Acting on M phase :

Taxanes :

- Paclitaxel.
- Docetaxel.

Vinca alkaloids.

Cycle non-specific :

Alkylating agents :

- Cyclophosphamide.
- Ifosfamide.


Platinum agents :

- Carboplatin.
- Cisplatin.

Features of tumors :

- If there is a tumour, more cells are in the active phase i.e, G₁ > G₀.
- Hence the cells are more chemosensitive.
- Doubling time :
 - Time taken for tumor to double in size.
 - Depends on actively dividing cells (Growth fraction).
 - The more number of active cells in growth phase, the greater is the growth fraction.
- Tumor with high GF have a high chemotherapy cure. Eg : GTN, ovarian germ cell tumors.

- Tumor vol is reduced by Sx or CTx and the remaining cells move from G₀ to G₁ phase.
- Log cell kill : Constant fraction of cells are killed.



During early stages of tumor expansion, growth is exponential, but with enlargement, tumor growth slows. Consequently, most tumors have completed their exponential growth phase at the time of clinical detection.

The Growth curve of tumor cells.

Uses of chemotherapy


00:23:52

Types of chemotherapy :

1. Induction chemotherapy.
 - Primary Rx.
 - Used in advanced malignancy & when there is no alternative Rx.
2. Adjuvant chemotherapy.
 - To destroy microscopic cells after primary tumor removed by Sx.
3. Neoadjuvant chemotherapy.
 - Used in advanced Ca.
 - Given prior to the surgery.
4. Maintenance (Consolidation) chemotherapy.
 - Given after treatment, to maintain prolonged duration of remission.
5. Salvage (Palliative) chemotherapy.
 - Refractory to Rx.
 - Palliate and stabilise with maintaining QOL.

Therapeutic window :

- Chemotherapeutic agents have a narrow therapeutic window.
- The effectiveness starts from the minimum effective dose upto the minimum toxic dose.
- Therapeutic index = median lethal dose - median effective dose.



Combination chemotherapy :

- more effective in attacking heterogenous population
- Different MOA decreases drug resistance
- Has a synergistic effect.
- Optimal dose & schedule to be used.
- There will be different toxicities which are at manageable level.
- Sequencing with other modalities like Sx or RTx.
- more commonly used combination is carboplatin + paclitaxel.

Dosing :

- BSA based : Dosing in mg/m^2
- Dose intensity :
Increasing the dose without increasing the frequency.
Risk of toxicity.
- Dose density :
Increase the frequency and reduce the dose accordingly.
- Routes : Oral/iv/sc/im/ip.

Extravasation :

One of the effect of toxicities is the extravasation injury.

Types of extravasation :

- **Vesicants** : Agents capable of causing skin ulceration and tissue necrosis on extravasation.
- **Exfoliant** : Agents capable of causing skin exfoliation on extravasation.
- **Irritant** : Agents capable of causing skin irritation on extravasation.
- **Inflammant** : Agents capable of causing skin inflammation on extravasation.

management :

- Stop infusion → elevate affected arm → Ice packs.
- If severe → Plastic Sx.
- may require analgesics/antiemetics/antibiotics.

Chemotherapeutic agents and their association with extravasation injury

Vesicants	Exfoliants	Irritants	Inflamnants	Neutral
Dactinomycin	Cisplatin	Carboplatin	Methotrexate	Bleomycin
Doxorubicin	Docetaxel	Etoposide		Cyclophosphamide
Paclitaxel	Liposomal doxorubicin			Gemcitabine
	Topotecan			Ifosfamide

- Vesicant - Agent capable of causing skin ulceration and tissue necrosis on extravasation
- Exfoliant - Agent capable of causing skin exfoliation on extravasation
- Irritant - Agent capable of causing skin irritation on extravasation
- Inflammant - Agent capable of causing skin inflammation on extravasation

Hypersensitivity reactions :

One of the common agent causing hypersensitivity is paclitaxel.

management :

Management of Hypersensitivity Reactions

1.	Stop the chemotherapy infusion
2.	Assess the patient's airway, breathing, and circulation
3.	Administer intravenous normal saline if hypotensive
4.	Administer oxygen if dyspneic or hypoxic
5.	Administer intravenous antihistamine (e.g., 50 mg intravenous diphenhydramine or 25-50 mg intravenous promethazine)
6.	Administer 5 mg of nebulized salbutamol if the patient has bronchospasm
7.	Administer intravenous corticosteroids (e.g., 100 mg of hydrocortisone); this may have no effect on the initial reaction, but may prevent rebound or prolonged allergic manifestations
8.	If the patient does not promptly improve or has symptoms of persistent or severe hypotension or persistent bronchospasm or laryngeal edema, administer adrenaline or epinephrine (0.1-0.25 mg intravenous); further acute resuscitation measures may be required
9.	Reassure the patient that the problem is a recognized and treatable one

Note :

methotrexate interacts with warfarin. Hence the dose of warfarin must be decreased if given along with methotrexate.

Drug resistance and response

00:45:10

Resistance :

Drug resistance can be :

- Intrinsic.
- Acquired.

Causes :

- Increased drug efflux.
- Inactivation of the drugs.
- Target is inactivated/changed.
- Activation of DNA repair.
- Reversion of mutations.

Response :

Response is based on response evaluation criteria in solid tumors (RECIST) criteria.

Clinical end points in evaluating response to chemotherapy

End Point	Definition
Complete response (CR)	Disappearance of all measurable "target" lesions
Partial response (PR)	A decrease of $\geq 30\%$ in the sum of diameters of all target lesions
Progressive disease (PD)	An increase of $\geq 20\%$ in the sum of diameters of target lesions or the identification of one or more new lesions
Stable disease (SD)	Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD

Chemotherapeutic agents


00:52:41

Antimetabolites :

- Analogues of naturally occurring components of metabolic pathways.
- S phase specific.
- Effective in rapidly growing tumor with short doubling time and large GF.

methotrexate :

- Indication : GTN.
- Blocks DHFR
- Route : Oral/im/iv/it.
- 8 day regime.
- Given on days 1, 3, 5, 7. Dose : 50 mg/m^2



methotrexate action.

Leucovorin :

- Given on days 2, 4, 6, 8.
- Dose : 0.1 mg/kg .
- Toxicity : myelo suppression/renal toxicity/cerebral dysfunction.

Gemcitabine :

- Indications : Recurrent ovarian carcinoma/uterine sarcoma.
- Synthetic nucleoside analogue.
- 30 min infusion. Dose : 1250 mg/m^2 once weekly for 3 wks with one week off.

Chemotherapy antimetabolites used for gynecologic cancer

Generic name	Brand name	Indications	Routes	Common dosages	Common toxicity
Methotrexate	Trexall, Rheumatrex	GTN	PO, IM, IV, intrathecal	IM: 1 mg/kg on days 1, 3, 5, 7 of 8-day cycle or $30\text{-}50 \text{ mg/m}^2/\text{wk}$ IV: 100 mg/m^2 during 30 min, then 200 mg/m^2 during 12 hr	BMD, mucositis, renal toxicity, CNS dysfunction
Gemcitabine	Gemzar	Recurrent ovarian CA, uterine sarcoma	IV	$600\text{-}1250 \text{ mg/m}^2/\text{wk}$ over 30 min $\times$ 2-3 wk	BMD, N/V/D, malaise and fever
5-Fluorouracil	Adrucil	Cervical CA, vulvar CA	IV	$800\text{-}1000 \text{ mg/m}^2/\text{d}$ during 96 hr	Mucositis, PPE
	Efludex	VAIN	Vaginal cream	$3 \text{ mL QOD} \times 1 \text{ wk}$, then weekly up to 10 wk	Vulvovaginal irritation

BMD - Bone marrow depression	N/V/D - Nausea, vomiting, and diarrhea
CA - Cancer	PPE - Palmar-plantar erythrodysesthesia
CNS - Central nervous system	PO - Orally
GTN - Gestational trophoblastic neoplasia	QOD - Every other day
IM - Intramuscular	VAIN - Vaginal intraepithelial neoplasia
IV - Intravenous	

Antitumour antibiotics :

Actinomycin D :

- Indication : GTN.
- Single agent or combination (EMA CO).
- Pulse dose : 1.25 mg IV push every other week.
- Toxicities : BMD, alopecia, vesicant.

Bleomycin :

- Used in BEP regime for GCT.
- Role in G2 phase, palliative for pleural effusion by pleurodesis.

- Pulmonary toxicity :

Seen in 10% with 1% death prevalence.

If DLCO is decreased by 15-30% → Impending pulmonary toxicity →

Drug must be stopped.

Dose >400 U is not recommended.

Doxorubicin :

- Indication : Ovarian carcinoma/uterine sarcoma.

- Intercalate with DNA, inhibit topoisomerase II and produces free radicals.

- Dose : 60 mg/m^2 3 weekly.

- Toxicity :

Cardio toxicity (if cumulative dose >550).

Pegylated liposomal doxorubicin decreases cardiotoxicity, but increases palmo plantar erythrodysesthesia.

Dose : 40 mg/m^2 every 4 weekly.

Chemotherapeutic antibiotics used for gynecologic cancer

Generic name	Brand name	Indications	Route	Dosages	Toxicity
Actinomycin D (dactinomycin)	Coarsegen	GTN	IV	1.25 mg IV push every other wk or 0.5 mg on days 1-5, every 2-3 wk	BMD, N/V/D, alopecia, vesicant
Bleomycin	Blenoxane	Germ cell or EGST ovarian CA, GTN	IV, IM, SC, intrapleural	IV 20 U/m ² (maximum dose of 30 U), every 3 wk	Pulmonary toxicity, fever, skin reaction
Doxorubicin	Adriamycin	Uterine sarcoma, recurrent epithelial ovarian CA	IV	45-60 mg/m ² every 3 wk	BMD, cardiac toxicity, alopecia, vesicant
Liposomal doxorubicin	Doxil	Recurrent epithelial ovarian CA	IV	40-60 mg/m ² over 30 min, every 4 wk	FPE, stomatitis, infusion reaction

Plant alkaloids :

Taxanes :

- Paclitaxel/docetaxel.
- Cell cycle specific.
- Acts on m phase.
- Derived from yew tree.
- Prevent depolymerization of spindle.
- Toxicity : myelosuppression, hypersensitivity reaction, peripheral neuropathy.

Chemotherapeutic plant alkaloids used for gynecologic cancer

Generic name	Brand name	Indications	Routes	Dosages	Toxicity
Paclitaxel	Taxol	Recurrent epithelial ovarian CA, endometrial CA, cervical CA, GTN	IV, IP	IV: 135-175 mg/m ² every 3 wk, or 80 mg/m ² /wk for 3 weeks IP: 60 mg/m ² on day 8 following a day-1 IV dose	HSR, peripheral neurotoxicity, BMD, alopecia, bradycardia, and arrhythmia
Docetaxel	Taxotere	Recurrent epithelial ovarian CA, uterine sarcoma	IV	75-100 mg/m ² every 3 weeks, or 35 mg/m ² /week for 3 weeks	BMD, peripheral edema, HSR, alopecia
Vincristine	Oncovin	GTN	IV	0.8-1.0 mg/m ² every other week	Neurotoxicity, abdominal pain, alopecia
Etoposide	VP-16	Germ cell or SCST ovarian CA; recurrent epithelial ovarian CA	IV, PO	IV: 100 mg/m ² days 1 & 2, every 2 wk, or 75-100 mg/m ² , days 1-5, every 3 wk PO: 50 mg/m ² /day for 3 wk	BMD, alopecia, secondary cancers
Topotecan	Hycamtin	Recurrent epithelial ovarian CA, cervical CA	IV	1.5 mg/m ² /d, days 1-5, every 3 wk, or 4 mg/m ² /wk for 3 wk, or 0.75 mg/m ² /d, days 1-3, every 3 wk	BMD, N/V, alopecia, fever, malaise

Platinum compounds :

Carboplatin :

- Produce DNA adducts and inhibit DNA synthesis.
- Toxicity : myelosuppression (Thrombocytopenia).
- Dose calculation : Based on area of the curve (AUC) which is based on GFR.
- Calvert formula : Carboplatin total dose (mg) = AUC × (GFR + 25). GFR = Creatinine clearance.
- Cockcroft-Gault equation : Cr. clearance = $(140 - \text{age}) \times \text{wt} / 0.72 \times \text{S. Cr.}$

Cisplatin :

- Toxicity : Nephrotoxicity, neurotoxicity and ototoxicity. Myelosuppression is less common.

PRINCIPLES OF RADIOTHERAPY : I

Introduction

00:00:32

Features :


- Radiation therapy is a critical component in the multidisciplinary management of majority of adult female cancers.
- Primary therapeutic modality in advanced cervix, vulvar, and vaginal cancers (As m/c histology is squamous cell CA/SCC).
- Adenocarcinomas originating uterine cancers : Radiation is often indicated as adjuvant therapy, post-resection.

Role of radiotherapy :

Intent.	Site.
Curative.	Cervix, vulva, vagina, uterus.
Adjunctive to surgery.	Cervix, vulva, vagina, uterus.
Palliative.	metastasis causing symptoms : Bleeding, pain, obstruction.

Principle of radiotherapy :

- **Ionising radiation** is used.
- Atom is converted into ion.
- Both direct and indirect DNA damage.
- Incident photon energises the inner shell electron → Energised electron moves out → void of electron → Electron from the outer shell comes to inner shell → An amount of energy is released in the form of photon.
- **Compton effect** : Incident photon does not give the entire energy → electron itself gets displaced and another photon is separated.
- **Pair production** : Incident photon will cause the release of an electron and positron → Releases a large amount of energy in the form of photon.



Types of radiotherapy :

Radiation treatments can be performed in two different ways :

1. External beam radiation therapy (EBRT)/teletherapy : Radiation source is at a distance from the target organ.
2. Brachytherapy :
 - Interstitial brachytherapy : Radiation source is kept directly into the tumour.
 - Intracavitary brachytherapy : Radiation source is kept into the body cavity close to the tumour.

EBRT

00:09:38

Types of EBRT :

Conventional :


- Lateral view field and AP-PA view field is present.
- Maximise the ionising radiation to the tumour.
- Uses single or opposing beams, with or without 2D dose distributions, with compensators and simple shielding for organs at risk (OAR).
- Less conformity.

3DCRT (3D Conformal Radiotherapy) :

- 3D images like CT and MRI images are used.
- Target volume delineation of tumour and normal organs according to ICRU principles with 3D dose calculations using MLC to shape beams.
- Multi-leaf collimators.


IMRT/IGRT :

- Intensity modulated radiotherapy.
- Intensity of very single beam can be modulated.
- Collimators and subcollimators can be used to modulate the radiation beams.
- **Aims** : Get as closer/conformal to the shape of the tumour and reduce toxicity to the nearby organs.
- To shape the fluence of the beam.
- Dynamic treatments : Image guided radiotherapy (IGRT).



5 R's of radiobiology :

- i. Repair.
- ii. Repopulation.
- iii. Reassortment.
- iv. Reoxygenation.
- v. Radiosensitivity.



Effect of ionizing radiation.

Repair :

- Dose of 90 Gy is required to kill the tumour.
- But a single dose can affect the nearby tissues : To avoid this fractions / fractionation of the dose is done.
- Repairing time required for tumour cells will be more as the repair mechanism would be damaged in the tumour cells when compared to normal cells.

Repopulation :


- **Late S phase** is the most radioresistant phase.
- **m phase** is the most radiosensitive phase.
- When the radiation is given to the tumour cell, not all the cells will be in G₂m phase → Cells in G₂m phase will get killed while the other cells are not killed → These cells will try to repopulate → To avoid this fractionation/fractions of doses are given.

Reassortment : Dose should be calculated based on normal cells and tumour cells in the tumour.

Reoxygenation :

- Oxygen is a very good radiosensitizer.
- **Radiosensitizer** : An element that is added with radiotherapy which has a synergistic effect.
- In well oxygenated tissue, radiotherapy is rapid as it releases more free radicals.
- While in less vascular/oxygenated tissue the radiotherapy is very slow → In anemia radiotherapy is difficult.


Note : When chemotherapy is given along with radiotherapy the dose of chemotherapy is reduced as radiotherapy has radiosensitising property.



Standard fractionation :

00:39:03

- Successful eradication of a localized cancer requires that the cancer cells be killed more rapidly and efficiently than surviving cancer cells can proliferate and repopulate.
- Delivery of this dose over the shortest feasible elapsed time will maximize efficacy along with deleterious consequences of a high dose per fraction on normal tissues.
- This can result in **delayed radiation injury** expressed months or years after therapy completion.
- Radiation delivered with curative intent is generally administered in daily treatments (Monday through Friday) of 1.8 Gy to 2.0 Gy.
- Cumulative doses range from 45 - 70 Gy.
- Risk of delayed injury is lessened when short courses of radiation are administered with palliative intent, often in dose fractions of 2.5 Gy to 4.0 Gy.



Dose response curve.

From the above graph fractionation helps in preventing toxicity to normal cells.

Hyperfractionation :

Increase the number of doses in a day but with constant total dose.

Accelerated hyperfractionation :

Increase the number of doses but decrease the total time.


Hypofractionation :

Increase in the dose but decrease in the total treatment time.

α/β ratio :

- As we increase the dose : Initially the effect is proportional to dose but later when the dose increased the effect becomes proportional to square of dose.
- This is called linear effect and quadratic equation.
- α is the linear effect while β is the quadratic effect.
- If the α/β ratio is higher (10) : Killing power is more.
- α/β ratio is lower in normal cells (3).
- Alpha/beta ratio $\rightarrow$ Response of normal tissues to radiation.

Dose-response curve for HDR irradiation



Cell killing by radiation is largely due to aberrations caused by breaks in two chromosomes. The dose response curve for HDR irradiation is linear quadratic: the two breaks may be caused by the same electron (dominant at low doses) or by two different electrons (dominant at higher doses). For LDR irradiation, where radiation is delivered over a protracted period, the principal mechanism of cell killing is by the single electron.

Early-responding tissues have a high alpha/beta ratio :


- manifest early reactions to radiation.
- Tissues with high proliferation rates such as bone marrow, reproductive organs and gastrointestinal tract mucosa.
- Preventatively, by administering multiple small radiation dose fractions, there is more sublethal damage repair, and early acute reactions can be decreased.

Late-responding tissues have low alpha/beta ratio :

- Clinical reactions only weeks-months after completion of radiotherapy.
- Slow to respond.
- Lung, kidney, spinal cord and brain are affected.
- more time is needed to repair sublethal damage, and thus high-dose per fraction radiation therapy.


LINAC :

- Linear accelerator.
- High speed electron beam activated by electric field
- Electrons are channelised to a heavy metal (Tungsten) : X rays (Photons) are released.
- Direct electron beam can be directed at a scattering foil : Electron beam becomes main source of radiation (Electron beam therapy) for superficial structures.




LINAC radiology machine.

Block diagram of a linear accelerator used to create external beam radiation



Differences between types of radiotherapy



A. Conventional radiotherapy

B. Conformal radiotherapy (CFRT) without intensity modulation

C. CFRT with intensity modulation (IMRT)

Steps :

- Initial consultation.
- Simulation (Imaging, immobilisation, tattooing).
- Treatment planning (Target volume delineation, contouring, dosing).
- Treatment delivery.
- Post-treatment follow up.

Planning technique :

- Positioning & Immobilization.
- Simulation.
- Field design.
- Beam energy.
- Dose & fractionation.

Positioning & Immobilization :

Patients may be positioned in :

- Supine position.
- Prone position with belly board.

Supine position is preferred because :

- most comfortable.
- Reproducible position.
- Stabilizes pelvis.
- Can be combined with immobilization devices.

Simulation :

- CT-based simulation is the m/c technique for gynecologic malignancies, treatment planning for both external beam radiotherapy (EBRT) and brachytherapy applications.
- Patient position : Supine with arms on the chest, knee and lower leg immobilisation to prevent pelvic rotation.
- Inferior border of tumour is marked with radio-opaque material.
- **Bladder protocol** is used to maintain a constant bladder filling 'comfortably full'.
- Orthogonal laser beams are aligned with anterior and lateral tattoos marked with radio-opaque material.
- AP and lateral simulator films are taken.
- Standard field borders are decided using bony anatomical landmarks (X ray sim).